Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Alzheimers Res Ther. 2022 May 21;14(1):70.
doi: 10.1186/s13195-022-00995-9.
3 BioArctic AB, Warfvinges väg 35, SE-112 51, Stockholm, Sweden.
4 Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
5 Berry Consultants, LLC, Austin, TX, USA.
6 Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA. [email protected].